Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction.

Letter by de Dios Regarding Article, "Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction". Circulation (2016) 1.39

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation (2016) 1.14

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J (2017) 0.80

Targeting heart failure with preserved ejection fraction: current status and future prospects. Vasc Health Risk Manag (2016) 0.80

Conventional Wisdom in Heart Failure Treatment Challenged Again: Does Heart Rate Lowering Worsen Exercise Intolerance in Heart Failure With Preserved Ejection Fraction? Circulation (2015) 0.75

Advances in the management of heart failure: the role of ivabradine. Vasc Health Risk Manag (2016) 0.75

What Is the Evidence That the Tissue Doppler Index E/e' Reflects Left Ventricular Filling Pressure Changes After Exercise or Pharmacological Intervention for Evaluating Diastolic Function? A Systematic Review. J Am Heart Assoc (2017) 0.75

Heart Failure with Preserved Ejection Fraction in Older Adults. Heart Fail Clin (2017) 0.75

Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med (2006) 17.13

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J (2012) 16.00

Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med (2006) 10.58

Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation (2009) 8.93

ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med (2003) 8.83

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12

Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med (2004) 8.12

Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48

Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA (2013) 5.41

Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 5.03

Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation (1991) 4.89

Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol (2011) 3.19

Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01

Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail (2010) 3.01

Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J (2007) 2.99

The role of the funny current in pacemaker activity. Circ Res (2010) 2.51

Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol (2013) 2.24

Regulation of stroke volume during submaximal and maximal upright exercise in normal man. Circ Res (1986) 2.15

Chronotropic incompetence and its contribution to exercise intolerance in older heart failure patients. J Cardiopulm Rehabil (2006) 2.10

Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation (2012) 2.03

Ventilatory and heart rate responses to exercise : better predictors of heart failure mortality than peak oxygen consumption. Circulation (1999) 1.88

Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction. Circ Heart Fail (2014) 1.84

Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail (2009) 1.84

Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation (2010) 1.72

Oxygen uptake efficiency slope: a new index of cardiorespiratory functional reserve derived from the relation between oxygen uptake and minute ventilation during incremental exercise. J Am Coll Cardiol (1996) 1.72

Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol (2009) 1.67

Control of in vivo left ventricular [correction] contraction/relaxation kinetics by myosin binding protein C: protein kinase A phosphorylation dependent and independent regulation. Circulation (2007) 1.55

The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol (2014) 1.48

Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart (2011) 1.41

Mechanism of augmented rate of left ventricular filling during exercise. Circ Res (1992) 1.31

Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. Eur J Heart Fail (2013) 1.30

Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol (2012) 1.28

International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation (2014) 1.28

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J (2014) 1.25

Disease-specific health-related quality of life questionnaires for heart failure: a systematic review with meta-analyses. Qual Life Res (2008) 1.18

Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail (2014) 1.06

Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA (2013) 0.79